AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001B04

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease

Identifieur interne : 001B04 ( PascalFrancis/Corpus ); précédent : 001B03; suivant : 001B05

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease

Auteurs : Victor L. Villemagne ; Nobuyuki Okamura ; Svetlana Pejoska ; John Drago ; Rachel S. Mulligan ; Gaël Chetelat ; Uwe Ackermann ; Graeme O'Keefe ; Gareth Jones ; Sylvia Gong ; Henry Tochon-Danguy ; Hank F. Kung ; Colin L. Masters ; Daniel M. Skovronsky ; Christopher C. Rowe

Source :

Archives of neurology : (Chicago) [ 0003-9942 ] ; 2011.

RBID : Pascal:11-0321403

Descripteurs français

Pascal (Inist)
- Démence à corps de Lewy, Démence d'Alzheimer, Pathologie du système nerveux, Transporteur vésiculaire monoamine.

English descriptors

KwdEn :
- Alzheimer disease, Lewy body dementia, Nervous system diseases, Vesicular monoamine transporter.

Abstract

Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand ¹⁸F 9-fluropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). Design, Setting, and Participants: Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [¹⁸F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region. Main Outcome Measure: Comparison of the tissue ratio for [¹⁸F]AV-133 between the different clinical diagnostic groups. Results: Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P<.001 ; effect size=2.1; anterior putamen: mean [SD], 0.90 [0.5] vs3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size =3.4). Compared with healthy controls, [¹⁸F] AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD. Conclusions: [¹⁸F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [¹⁸F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0003-9942`
A02	`01`			`@0 ARNEAS`
A03		`1`		`@0 Arch. neurol. : (Chic.)`
A05				`@2 68`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease`
A11	`01`	`1`		`@1 VILLEMAGNE (Victor L.)`
A11	`02`	`1`		`@1 OKAMURA (Nobuyuki)`
A11	`03`	`1`		`@1 PEJOSKA (Svetlana)`
A11	`04`	`1`		`@1 DRAGO (John)`
A11	`05`	`1`		`@1 MULLIGAN (Rachel S.)`
A11	`06`	`1`		`@1 CHETELAT (Gaël)`
A11	`07`	`1`		`@1 ACKERMANN (Uwe)`
A11	`08`	`1`		`@1 O'KEEFE (Graeme)`
A11	`09`	`1`		`@1 JONES (Gareth)`
A11	`10`	`1`		`@1 GONG (Sylvia)`
A11	`11`	`1`		`@1 TOCHON-DANGUY (Henry)`
A11	`12`	`1`		`@1 KUNG (Hank F.)`
A11	`13`	`1`		`@1 MASTERS (Colin L.)`
A11	`14`	`1`		`@1 SKOVRONSKY (Daniel M.)`
A11	`15`	`1`		`@1 ROWE (Christopher C.)`
A14	`01`			`@1 Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health @2 Heidelberg @3 DEU @Z 3 aut. @Z 5 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut. @Z 11 aut. @Z 15 aut.`
A14	`02`			`@1 Mental Health Research Institute, University of Melbourne @2 Melbourne, Victoria @3 AUS @Z 1 aut. @Z 13 aut.`
A14	`03`			`@1 Howard Florey Institute, University of Melbourne @2 Melbourne, Victoria @3 AUS @Z 4 aut.`
A14	`04`			`@1 Centre for Neuroscience, University of Melbourne @2 Melbourne, Victoria @3 AUS @Z 4 aut.`
A14	`05`			`@1 Department of Pharmacology, Tohoku University School of Medicine @2 Sendai @3 JPN @Z 2 aut.`
A14	`06`			`@1 Inserm-Ecole Practique des Hautes Études-Université de Caen/Basse-Normandie @2 Caen @3 FRA @Z 6 aut.`
A14	`07`			`@1 Department of Radiology, University of Pennsylvania @3 USA @Z 12 aut. @Z 14 aut.`
A14	`08`			`@1 Avid Radiopharmaceuticals Inc @2 Philadelphia @3 USA @Z 14 aut.`
A20				`@1 905-912`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2048B @5 354000190482230090`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 50 ref.`
A47	`01`	`1`		`@0 11-0321403`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Archives of neurology : (Chicago)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand ¹⁸F 9-fluropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). Design, Setting, and Participants: Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [¹⁸F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region. Main Outcome Measure: Comparison of the tissue ratio for [¹⁸F]AV-133 between the different clinical diagnostic groups. Results: Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P<.001 ; effect size=2.1; anterior putamen: mean [SD], 0.90 [0.5] vs3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size =3.4). Compared with healthy controls, [¹⁸F] AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD. Conclusions: [¹⁸F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [¹⁸F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Démence à corps de Lewy @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Lewy body dementia @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Demencia cuerpos Lewy @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Démence d'Alzheimer @5 02`
C03	`02`	`X`	`ENG`	`@0 Alzheimer disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Demencia Alzheimer @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Transporteur vésiculaire monoamine @4 CD @5 96`
C03	`04`	`X`	`ENG`	`@0 Vesicular monoamine transporter @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
N21				`@1 220`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0321403 INIST
ET :	In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease
AU :	VILLEMAGNE (Victor L.); OKAMURA (Nobuyuki); PEJOSKA (Svetlana); DRAGO (John); MULLIGAN (Rachel S.); CHETELAT (Gaël); ACKERMANN (Uwe); O'KEEFE (Graeme); JONES (Gareth); GONG (Sylvia); TOCHON-DANGUY (Henry); KUNG (Hank F.); MASTERS (Colin L.); SKOVRONSKY (Daniel M.); ROWE (Christopher C.)
AF :	Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health/Heidelberg/Allemagne (3 aut., 5 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 15 aut.); Mental Health Research Institute, University of Melbourne/Melbourne, Victoria/Australie (1 aut., 13 aut.); Howard Florey Institute, University of Melbourne/Melbourne, Victoria/Australie (4 aut.); Centre for Neuroscience, University of Melbourne/Melbourne, Victoria/Australie (4 aut.); Department of Pharmacology, Tohoku University School of Medicine/Sendai/Japon (2 aut.); Inserm-Ecole Practique des Hautes Études-Université de Caen/Basse-Normandie/Caen/France (6 aut.); Department of Radiology, University of Pennsylvania/Etats-Unis (12 aut., 14 aut.); Avid Radiopharmaceuticals Inc/Philadelphia/Etats-Unis (14 aut.)
DT :	Publication en série; Niveau analytique
SO :	Archives of neurology : (Chicago); ISSN 0003-9942; Coden ARNEAS; Etats-Unis; Da. 2011; Vol. 68; No. 7; Pp. 905-912; Bibl. 50 ref.
LA :	Anglais
EA :	Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand ¹⁸F 9-fluropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). Design, Setting, and Participants: Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [¹⁸F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region. Main Outcome Measure: Comparison of the tissue ratio for [¹⁸F]AV-133 between the different clinical diagnostic groups. Results: Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P<.001 ; effect size=2.1; anterior putamen: mean [SD], 0.90 [0.5] vs3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size =3.4). Compared with healthy controls, [¹⁸F] AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD. Conclusions: [¹⁸F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [¹⁸F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.
CC :	002B17; 002B17G
FD :	Démence à corps de Lewy; Démence d'Alzheimer; Pathologie du système nerveux; Transporteur vésiculaire monoamine
FG :	Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central
ED :	Lewy body dementia; Alzheimer disease; Nervous system diseases; Vesicular monoamine transporter
EG :	Cerebral disorder; Degenerative disease; Central nervous system disease
SD :	Demencia cuerpos Lewy; Demencia Alzheimer; Sistema nervioso patología
LO :	INIST-2048B.354000190482230090
ID :	11-0321403

Links to Exploration step

Pascal:11-0321403

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease</title>
<author><name sortKey="Villemagne, Victor L" sort="Villemagne, Victor L" uniqKey="Villemagne V" first="Victor L." last="Villemagne">Victor L. Villemagne</name>
<affiliation><inist:fA14 i1="02"><s1>Mental Health Research Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okamura, Nobuyuki" sort="Okamura, Nobuyuki" uniqKey="Okamura N" first="Nobuyuki" last="Okamura">Nobuyuki Okamura</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pharmacology, Tohoku University School of Medicine</s1>
<s2>Sendai</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pejoska, Svetlana" sort="Pejoska, Svetlana" uniqKey="Pejoska S" first="Svetlana" last="Pejoska">Svetlana Pejoska</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Drago, John" sort="Drago, John" uniqKey="Drago J" first="John" last="Drago">John Drago</name>
<affiliation><inist:fA14 i1="03"><s1>Howard Florey Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Centre for Neuroscience, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mulligan, Rachel S" sort="Mulligan, Rachel S" uniqKey="Mulligan R" first="Rachel S." last="Mulligan">Rachel S. Mulligan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chetelat, Gael" sort="Chetelat, Gael" uniqKey="Chetelat G" first="Gaël" last="Chetelat">Gaël Chetelat</name>
<affiliation><inist:fA14 i1="06"><s1>Inserm-Ecole Practique des Hautes Études-Université de Caen/Basse-Normandie</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ackermann, Uwe" sort="Ackermann, Uwe" uniqKey="Ackermann U" first="Uwe" last="Ackermann">Uwe Ackermann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="O Keefe, Graeme" sort="O Keefe, Graeme" uniqKey="O Keefe G" first="Graeme" last="O'Keefe">Graeme O'Keefe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jones, Gareth" sort="Jones, Gareth" uniqKey="Jones G" first="Gareth" last="Jones">Gareth Jones</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gong, Sylvia" sort="Gong, Sylvia" uniqKey="Gong S" first="Sylvia" last="Gong">Sylvia Gong</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tochon Danguy, Henry" sort="Tochon Danguy, Henry" uniqKey="Tochon Danguy H" first="Henry" last="Tochon-Danguy">Henry Tochon-Danguy</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kung, Hank F" sort="Kung, Hank F" uniqKey="Kung H" first="Hank F." last="Kung">Hank F. Kung</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Radiology, University of Pennsylvania</s1>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Masters, Colin L" sort="Masters, Colin L" uniqKey="Masters C" first="Colin L." last="Masters">Colin L. Masters</name>
<affiliation><inist:fA14 i1="02"><s1>Mental Health Research Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Skovronsky, Daniel M" sort="Skovronsky, Daniel M" uniqKey="Skovronsky D" first="Daniel M." last="Skovronsky">Daniel M. Skovronsky</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Radiology, University of Pennsylvania</s1>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Avid Radiopharmaceuticals Inc</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rowe, Christopher C" sort="Rowe, Christopher C" uniqKey="Rowe C" first="Christopher C." last="Rowe">Christopher C. Rowe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0321403</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0321403 INIST</idno>
<idno type="RBID">Pascal:11-0321403</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B04</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease</title>
<author><name sortKey="Villemagne, Victor L" sort="Villemagne, Victor L" uniqKey="Villemagne V" first="Victor L." last="Villemagne">Victor L. Villemagne</name>
<affiliation><inist:fA14 i1="02"><s1>Mental Health Research Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okamura, Nobuyuki" sort="Okamura, Nobuyuki" uniqKey="Okamura N" first="Nobuyuki" last="Okamura">Nobuyuki Okamura</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pharmacology, Tohoku University School of Medicine</s1>
<s2>Sendai</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pejoska, Svetlana" sort="Pejoska, Svetlana" uniqKey="Pejoska S" first="Svetlana" last="Pejoska">Svetlana Pejoska</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Drago, John" sort="Drago, John" uniqKey="Drago J" first="John" last="Drago">John Drago</name>
<affiliation><inist:fA14 i1="03"><s1>Howard Florey Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Centre for Neuroscience, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mulligan, Rachel S" sort="Mulligan, Rachel S" uniqKey="Mulligan R" first="Rachel S." last="Mulligan">Rachel S. Mulligan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chetelat, Gael" sort="Chetelat, Gael" uniqKey="Chetelat G" first="Gaël" last="Chetelat">Gaël Chetelat</name>
<affiliation><inist:fA14 i1="06"><s1>Inserm-Ecole Practique des Hautes Études-Université de Caen/Basse-Normandie</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ackermann, Uwe" sort="Ackermann, Uwe" uniqKey="Ackermann U" first="Uwe" last="Ackermann">Uwe Ackermann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="O Keefe, Graeme" sort="O Keefe, Graeme" uniqKey="O Keefe G" first="Graeme" last="O'Keefe">Graeme O'Keefe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jones, Gareth" sort="Jones, Gareth" uniqKey="Jones G" first="Gareth" last="Jones">Gareth Jones</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gong, Sylvia" sort="Gong, Sylvia" uniqKey="Gong S" first="Sylvia" last="Gong">Sylvia Gong</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tochon Danguy, Henry" sort="Tochon Danguy, Henry" uniqKey="Tochon Danguy H" first="Henry" last="Tochon-Danguy">Henry Tochon-Danguy</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kung, Hank F" sort="Kung, Hank F" uniqKey="Kung H" first="Hank F." last="Kung">Hank F. Kung</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Radiology, University of Pennsylvania</s1>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Masters, Colin L" sort="Masters, Colin L" uniqKey="Masters C" first="Colin L." last="Masters">Colin L. Masters</name>
<affiliation><inist:fA14 i1="02"><s1>Mental Health Research Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Skovronsky, Daniel M" sort="Skovronsky, Daniel M" uniqKey="Skovronsky D" first="Daniel M." last="Skovronsky">Daniel M. Skovronsky</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Radiology, University of Pennsylvania</s1>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Avid Radiopharmaceuticals Inc</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rowe, Christopher C" sort="Rowe, Christopher C" uniqKey="Rowe C" first="Christopher C." last="Rowe">Christopher C. Rowe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Lewy body dementia</term>
<term>Nervous system diseases</term>
<term>Vesicular monoamine transporter</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Démence à corps de Lewy</term>
<term>Démence d'Alzheimer</term>
<term>Pathologie du   système nerveux</term>
<term>Transporteur vésiculaire monoamine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand <sup>18</sup>
F 9-fluropropyl-(+)-dihydrotetrabenazine ([<sup>18</sup>
F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). Design, Setting, and Participants: Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [<sup>18</sup>
F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region. Main Outcome Measure: Comparison of the tissue ratio for [<sup>18</sup>
F]AV-133 between the different clinical diagnostic groups. Results: Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P<.001 ; effect size=2.1; anterior putamen: mean [SD], 0.90 [0.5] vs3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size =3.4). Compared with healthy controls, [<sup>18</sup>
F] AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD. Conclusions: [<sup>18</sup>
F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [<sup>18</sup>
F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-9942</s0>
</fA01>
<fA02 i1="01"><s0>ARNEAS</s0>
</fA02>
<fA03 i2="1"><s0>Arch. neurol. : (Chic.)</s0>
</fA03>
<fA05><s2>68</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VILLEMAGNE (Victor L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OKAMURA (Nobuyuki)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PEJOSKA (Svetlana)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DRAGO (John)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MULLIGAN (Rachel S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHETELAT (Gaël)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ACKERMANN (Uwe)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>O'KEEFE (Graeme)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>JONES (Gareth)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GONG (Sylvia)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>TOCHON-DANGUY (Henry)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>KUNG (Hank F.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>MASTERS (Colin L.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>SKOVRONSKY (Daniel M.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>ROWE (Christopher C.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Mental Health Research Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Howard Florey Institute, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Centre for Neuroscience, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Pharmacology, Tohoku University School of Medicine</s1>
<s2>Sendai</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Inserm-Ecole Practique des Hautes Études-Université de Caen/Basse-Normandie</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Radiology, University of Pennsylvania</s1>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Avid Radiopharmaceuticals Inc</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA20><s1>905-912</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2048B</s2>
<s5>354000190482230090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>50 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0321403</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Archives of neurology : (Chicago)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand <sup>18</sup>
F 9-fluropropyl-(+)-dihydrotetrabenazine ([<sup>18</sup>
F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). Design, Setting, and Participants: Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [<sup>18</sup>
F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region. Main Outcome Measure: Comparison of the tissue ratio for [<sup>18</sup>
F]AV-133 between the different clinical diagnostic groups. Results: Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P<.001 ; effect size=2.1; anterior putamen: mean [SD], 0.90 [0.5] vs3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size =3.4). Compared with healthy controls, [<sup>18</sup>
F] AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD. Conclusions: [<sup>18</sup>
F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [<sup>18</sup>
F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Démence à corps de Lewy</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lewy body dementia</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Demencia cuerpos Lewy</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Démence d'Alzheimer</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Transporteur vésiculaire monoamine</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vesicular monoamine transporter</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fN21><s1>220</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0321403 INIST</NO>
<ET>In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease</ET>
<AU>VILLEMAGNE (Victor L.); OKAMURA (Nobuyuki); PEJOSKA (Svetlana); DRAGO (John); MULLIGAN (Rachel S.); CHETELAT (Gaël); ACKERMANN (Uwe); O'KEEFE (Graeme); JONES (Gareth); GONG (Sylvia); TOCHON-DANGUY (Henry); KUNG (Hank F.); MASTERS (Colin L.); SKOVRONSKY (Daniel M.); ROWE (Christopher C.)</AU>
<AF>Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health/Heidelberg/Allemagne (3 aut., 5 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 15 aut.); Mental Health Research Institute, University of Melbourne/Melbourne, Victoria/Australie (1 aut., 13 aut.); Howard Florey Institute, University of Melbourne/Melbourne, Victoria/Australie (4 aut.); Centre for Neuroscience, University of Melbourne/Melbourne, Victoria/Australie (4 aut.); Department of Pharmacology, Tohoku University School of Medicine/Sendai/Japon (2 aut.); Inserm-Ecole Practique des Hautes Études-Université de Caen/Basse-Normandie/Caen/France (6 aut.); Department of Radiology, University of Pennsylvania/Etats-Unis (12 aut., 14 aut.); Avid Radiopharmaceuticals Inc/Philadelphia/Etats-Unis (14 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Archives of neurology : (Chicago); ISSN 0003-9942; Coden ARNEAS; Etats-Unis; Da. 2011; Vol. 68; No. 7; Pp. 905-912; Bibl. 50 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand <sup>18</sup>
F 9-fluropropyl-(+)-dihydrotetrabenazine ([<sup>18</sup>
F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). Design, Setting, and Participants: Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [<sup>18</sup>
F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region. Main Outcome Measure: Comparison of the tissue ratio for [<sup>18</sup>
F]AV-133 between the different clinical diagnostic groups. Results: Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P<.001 ; effect size=2.1; anterior putamen: mean [SD], 0.90 [0.5] vs3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size =3.4). Compared with healthy controls, [<sup>18</sup>
F] AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD. Conclusions: [<sup>18</sup>
F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [<sup>18</sup>
F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Démence à corps de Lewy; Démence d'Alzheimer; Pathologie du   système nerveux; Transporteur vésiculaire monoamine</FD>
<FG>Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Lewy body dementia; Alzheimer disease; Nervous system diseases; Vesicular monoamine transporter</ED>
<EG>Cerebral disorder; Degenerative disease; Central nervous system disease</EG>
<SD>Demencia cuerpos Lewy; Demencia Alzheimer; Sistema nervioso patología</SD>
<LO>INIST-2048B.354000190482230090</LO>
<ID>11-0321403</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B04 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B04 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0321403
   |texte=   In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri